Table 2.
Multivariate analysis of risk factors for OS and PFS
| OS | PFS | |||||
|---|---|---|---|---|---|---|
| HR | (95 % CI) | P | HR | (95 % CI) | P | |
| Revised IPI | 1.92 | (0.58–6.36) | 0.287 | 3.37 | (1.35–8.39) | 0.009 |
| Low SUVmax | 2.51 | (0.31–20.03) | 0.385 | 7.49 | (1.00–55.95) | 0.049 |
| Bulky mass | 1.02 | (0.21–4.99) | 0.979 | 1.29 | (0.37–4.51) | 0.693 |
| sIL-2R >normal | 2.31 | (0.27–19.42) | 0.441 | 0.85 | (0.27–2.67) | 0.775 |
| Primary lesions except LNs | 1.49 | (0.42–5.23) | 0.533 | 1.01 | (0.44–2.29) | 0.988 |
OS overall survival, PFS progression-free survival, HR hazard ratio, 95 % CI 95 % confidence interval, IPI International Prognostic Index, SUV max maximum standardized uptake value, sIL-2R soluble interleukin-2 receptor, LNs lymph nodes